Serum asprosin levels as a subclinical atherosclerosis marker in patients with primary hypertension Authors: Mehmet İbrahim Özet, Fatih Acehan, Merve Kaygısız, Mustafa Abdulgani Kurt, Halil Arslan, Fatma Meriç Yılmaz, İhsan Ateş Published: 2026 ABSTRACT AbstractHypertension and subclinical atherosclerosis are major contributors to cardiovascular morbidity. Asprosin, a fasting-induced adipokine involved in glucose homeostasis and inflammation, has been proposed as a novel metabolic biomarker. This study investigated the relationship between serum asprosin levels and subclinical atherosclerosis in patients with primary hypertension. A total of 114 patients with primary hypertension and 62 age- and sex-matched healthy controls were enrolled between July 2022 and June 2023. Coronary artery calcium (Agatston) score was used to assess subclinical atherosclerosis. Serum asprosin concentrations were measured using the ELISA method. Correlation, regression, and ROC analyses were performed to identify determinants and discriminatory performance. Serum asprosin levels were significantly higher in hypertensive patients than in controls (3.0 ± 0.9 ng/mL vs. 2.6 ± 0.8 ng/mL, p = 0.012). In hypertensive individuals, increasing age, blood pressure, and ASCVD risk score were independently associated with higher atherosclerotic burden, whereas the neutrophil-to-lymphocyte ratio (NLR) was inversely related (p < 0.05). ROC analysis showed that serum asprosin could discriminate hypertensive patients with subclinical atherosclerosis (AUC = 0.710 [95% CI: 0.62–0.80, p = 0.001]) at a cut-off > 3.05 ng/mL, with 69% sensitivity and 72% specificity. Serum asprosin levels were elevated in patients with primary hypertension and may reflect metabolic-inflammatory alterations rather than directly indicate subclinical atherosclerosis. Given its modest discriminatory performance, serum asprosin should be considered an exploratory and complementary biomarker, not a standalone clinical tool. Larger longitudinal studies are required to validate its clinical relevance. Clinical trial number Not applicable.Keywords: Asprosin, Hypertension, Subclinical atherosclerosis, Coronary artery calcium, Inflammation Introduction Hypertension is a major public health concern worldwide and is one of the most significant risk factors for cardiovascular diseases (CVD), cerebrovascular events, and kidney failure [1–5]. According to data from the World Health Organization (WHO) and the European Society of Cardiology (ESC), approximately 31% of the adult population globally has been diagnosed with hypertension [6]. It is a chronic disease that is often asymptomatic but, if left uncontrolled, can lead to target organ damage and an increased risk of mortality. Atherosclerosis is a pathological process characterized by lipid accumulation, inflammatory cell infiltration, and fibrotic changes in the arterial wall, forming the fundamental basis of cardiovascular diseases [7, 8]. It is a progressive condition that may remain asymptomatic in its early stages. Therefore, early detection of subclinical atherosclerosis before clinically overt cardiovascular events, such as myocardial infarction or ischemic stroke, is crucial [9]. Although various imaging techniques are used to identify subclinical atherosclerosis, one of the most commonly employed methods in clinical practice is the coronary artery calcium (CAC) score, also known as the Agatston score [10–14]. This score quantifies coronary artery calcification and helps in assessing an individual’s cardiovascular risk. In recent years, several metabolically active biomarkers have been implicated in hypertension and cardiovascular disease. Asprosin, a fasting-induced adipokine secreted by white adipose tissue, regulates hepatic glucose release and has been associated with insulin resistance, obesity, dyslipidemia, and systemic inflammation [15–22]. Because hypertension is closely linked to metabolic and inflammatory dysregulation, serum asprosin has emerged as a potential complementary biomarker in cardiovascular research. However, its relationship with subclinical atherosclerosis and coronary artery calcification remains insufficiently understood. Recent evidence has further highlighted the complex and context-dependent role of asprosin in cardiovascular disease, suggesting that its biological effects may vary according to metabolic status, inflammatory burden, and vascular microenvironment. These findings support the growing interest in asprosin as a potential cardiovascular biomarker and therapeutic target [23]. In this study, we aimed to evaluate the relationship between serum asprosin levels and subclinical atherosclerosis in patients with primary hypertension and to determine whether serum asprosin levels are associated with metabolic-inflammatory alterations and subclinical atherosclerosis in patients with primary hypertension. Materials and methods Study design and data collection This study was designed as a cross-sectional study and included patients diagnosed with primary hypertension who presented to the Internal Medicine Clinic of Ankara City Hospital between July 1, 2022, and June 30, 2023. The control group consisted of age- and sex-matched healthy individuals. Ethical approval was obtained from the local ethics committee, and informed consent was obtained from all participants. The study included 114 patients diagnosed with primary hypertension and 62 healthy individuals. Hypertension was diagnosed based on the 2018 guidelines of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), using an office blood pressure measurement with a systolic blood pressure (SBP) ≥ 140 mmHg and/or a diastolic blood pressure (DBP) ≥ 90 mmHg [6]. Only patients with primary hypertension were included, whereas those with secondary hypertension were excluded. Additionally, individuals with diabetes mellitus, chronic kidney disease, chronic inflammatory diseases, a history of myocardial infarction or stroke, and those using lipid-lowering or anti-inflammatory medications were excluded from the study. These exclusion criteria were applied to minimize major metabolic and inflammatory confounders that could independently influence serum asprosin levels and coronary artery calcification. However, this strict selection strategy may also have reduced the generalizability of the findings to broader real-world hypertensive populations. Demographic, clinical, and laboratory data were collected from all participants. Age, gender, and smoking status were recorded. Body mass index (BMI) and waist circumference were measured and documented. Blood pressure measurements were taken in a seated position after at least five minutes of rest, with three measurements taken from each arm, and the average value was calculated. The laboratory parameters assessed included fasting blood glucose, HbA1c, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, serum creatinine, C-reactive protein (CRP), and the neutrophil-to-lymphocyte ratio (NLR). Additionally, the duration of hypertension was recorded for hypertensive patients. Assessment of subclinical atherosclerosis To assess subclinical atherosclerosis, coronary artery calcium (CAC) scoring (Agatston score) was performed in all participants using multislice computed tomography (MSCT). The Agatston score, which quantifies coronary artery calcification, is a widely used marker for cardiovascular disease risk stratification. For subgroup analyses, CAC burden was categorized into four groups: no atherosclerosis (CAC = 0), mild CAC (CAC 1–10), moderate CAC (CAC 11–100), and severe CAC (CAC > 100). This categorization was selected to better distinguish early coronary calcification burden and to allow more detailed comparison across progressive stages of subclinical atherosclerosis. Measurement of serum asprosin levels Serum asprosin levels were measured from fasting blood samples collected from all participants. Blood samples were centrifuged at 4 °C, and serum was separated and stored at -80 °C until analysis. Serum asprosin levels were quantified using an enzyme-linked immunosorbent assay (ELISA). The ELISA kit was used according to the manufacturer’s protocol, and results were expressed in ng/mL (Fig. 1). Flow diagram illustrating patient selection, exclusion criteria, and final study cohort allocation for hypertensive patients and healthy controls Statistical analysis Statistical analysis was performed using SPSS 26.0 software (IBM Corp., Chicago, IL, USA). Data normality was assessed using the Kolmogorov–Smirnov and Shapiro–Wilk tests, in combination with histogram and Q–Q plot visual inspection. Normally distributed data were expressed as mean ± standard deviation (SD), while non-normally distributed data were presented as median (minimum–maximum) values. Differences between groups were analyzed using independent samples t-tests for normally distributed variables and Mann-Whitney U tests for non-normally distributed variables. Categorical variables were analyzed using the chi-square test. The correlation between serum asprosin levels and the Agatston score was assessed using Pearson’s or Spearman’s correlation analysis, depending on data distribution. The discriminatory performance of serum asprosin levels in hypertension was evaluated using receiver operating characteristic (ROC) curve analysis, and the area under the curve (AUC) was calculated to determine the cut-off value, sensitivity, and specificity of serum asprosin levels. A p-value < 0.05 was considered statistically significant. Multivariable regression analyses were performed using variables considered clinically relevant or statistically significant in univariable analyses. Age, blood pressure parameters, ASCVD risk score, lipid parameters, and inflammatory markers were evaluated as candidate covariates. To reduce the risk of multicollinearity, highly correlated variables were not entered simultaneously into the same regression model. Collinearity diagnostics were assessed using variance inflation factor (VIF) analysis, and no significant multicollinearity was detected among the included variables. Given the exploratory nature of the study and the limited sample size, correction for multiple comparisons was not applied; therefore, the findings should be interpreted cautiously. Results A total of 114 patients with primary hypertension and 62 healthy individuals were included in the study. When comparing the groups in terms of age and sex, no statistically significant difference was observed (p > 0.05). However, systolic and diastolic blood pressure values were found to be significantly higher in the hypertension group compared to the control group (p < 0.001). Similarly, body mass index (BMI) and waist circumference measurements were significantly higher in the hypertension group than in the control group (p < 0.05) (Table 1). Table 1Comparison of demographic, clinical, and atherosclerosis-related findingsVariablesTotal Population (n = 176)ControlGroup (n = 62)HypertensionGroup (n = 114)p-valueMean ± SD or n (%) or Median (IQR)Age (years)57.9 ± 7.653.9 ± 7.560.1 ± 6.8< 0.001*Gender Male101 (57.4)35 (56.5)66 (57.9)0.853 Female75 (42.6)27 (43.5)48 (42.1)Height (cm)166.8 ± 9.7165.8 ± 9.4167.3 ± 9.80.350Weight (kg)79.2 ± 12.676.2 ± 10.580.8 ± 13.40.021*BMI28.5 ± 4.027.8 ± 3.528.9 ± 4.30.070Smoking Never Smoked68 (38.6)27 (43.5)41 (36.0)0.184 Smoker59 (33.5)23 (37.1)36 (31.6) Former Smoker49 (27.8)12 (19.4)37 (32.5)Pack-Years5 (0–90)2.5 (0–90)6 (0–80)0.201SBP (mmHg)135.4 ± 15.4126.1 ± 6.4138.2 ± 16.2< 0.001*DBP (mmHg)82.1 ± 10.079.1 ± 6.583.6 ± 10.60.012*HT Duration (years)0.7 (0.1–42.0)05 (0.1–42.0)< 0.001*Agatston Score6 (0-1025)0 (0-303)7 (0-1025)0.210Atherosclerosis No57 (39.6)15 (50.0)42 (36.8)0.212 Yes87 (60.4)15 (50.0)72 (63.2)Coronary Artery Calcium (CAC) Burden0.657None57 (39.6)15 (50.0)42 (36.8)Mild CAC22 (15.3)3 (10.0)18 (15.8)Moderate CAC35 (24.3)8 (26.7)30 (35.7)Severe CAC22 (15.3)3 (10.0)19 (16.7)ASCVD Risk Score, %11.0 (1.2–32)9.5 (5.8–19.3)11.2 (1.2–32)0.127Risk Categories0.129Low7 (4.9)07 (6.1)Borderline21 (14.6)5 (16.7)16 (14.0)Moderate104 (72.2)25 (83.3)79 (69.3)High12 (8.3)012 (10.5)Asprosin, ng/mL2.9 ± 0.92.6 ± 0.83.0 ± 0.90.012*Glucose, mg/dL88.5 ± 11.385.7 ± 9.690.1 ± 11.90.015*Urea, mg/dL30.8 ± 8.730.2 ± 7.831.1 ± 9.10.487Creatinine, mg/dL0.8 ± 0.20.8 ± 0.20.8 ± 0.20.421AST, U/L23 (11–130)24 (13–130)22 (11–78)0.206ALT, U/L23 (9-117)23 (10–117)23 (9–69)0.989ALP, U/L78.5 (29–220)78.5 (29–220)78.5 (37–140)0.779GGT, U/L21 (4-135)20.5 (4-135)21 (7–70)0.817Total Cholesterol, mg/dL210.2 ± 36.7207.8 ± 43.4211.5 ± 32.60.555Triglycerides, mg/dL136.5 (41-1056)124.5 (42–349)142.5 (41-1056)0.817HDL-C, mg/dL48.5 ± 14.048.4 ± 13.848.5 ± 14.20.944LDL-C, mg/dL129.0 ± 31.4129.1 ± 37.1128.9 ± 28.10.970Non-HDL-C, mg/dL161.7 ± 36.6159.4 ± 43.7163.0 ± 32.20.572TyG Index4.7 ± 0.34.7 ± 0.34.8 ± 0.30.024*HbA1c, %5.6 ± 0.45.5 ± 0.55.6 ± 0.30.180Hemoglobin, g/dL14.4 ± 1.414.1 ± 1.514.4 ± 1.30.207WBC, ×10⁹/L7.3 ± 1.96.9 ± 1.87.5 ± 2.00.019*Neutrophils, ×10⁹/L4.3 ± 1.44.1 ± 1.24.4 ± 1.50.073Lymphocytes, ×10⁹/L2.5 ± 0.82.6 ± 0.82.5 ± 0.70.192Platelets, ×10⁹/L260.7 ± 61.2258.9 ± 58.7261.7 ± 62.90.041*NLR1.9 (0.8–11.5)1.8 (0.9–11.5)1.9 (0.8–6.2)0.959 Comparison of demographic, clinical, and atherosclerosis-related findings In terms of laboratory parameters, fasting blood glucose, triglyceride, and LDL cholesterol levels were found to be significantly higher in patients with hypertension compared to the control group (p < 0.05). In contrast, HDL cholesterol levels were significantly lower in the hypertension group than in the control group (p < 0.05). Additionally, CRP and the NLR were significantly elevated in hypertensive patients (p < 0.05) (Table 1.). Atherosclerotic plaque burden in hypertensive patients Comparison of demographic and clinical findings according to CAC categories (no atherosclerosis, mild CAC, moderate CAC, and severe CAC) is presented in Table 2. Patients in the moderate CAC group had the highest mean age among all subgroups (p = 0.041). Systolic and diastolic blood pressure values progressively increased across CAC burden categories and were highest in the severe CAC group (p = 0.020 for both). Similarly, ASCVD risk scores were significantly higher in the moderate and severe CAC groups compared with the no atherosclerosis and mild CAC groups (p = 0.040). No significant differences were observed in laboratory findings among CAC burden categories (p > 0.05) (Table 2). Table 2Comparison of demographic and clinical characteristics according to coronary artery calcium categories in hypertensive patientsVariablesNoAtherosclerosis(CAC = 0)(n = 42)Coronary Artery Calcium Burden CategoriesMild CAC(CAC 1–10)(n = 18)Moderate CAC(CAC 11–100) (n = 35)Severe CAC(CAC > 100)(n = 19)P valueAge (years)58.8 ± 7.158.0 ± 7.862.6 ± 5.560.4 ± 6.3 0.041* Gender, n (%)0.446 Male22 (52.4)11 (61.1)19 (54.3)14 (73.7) Female20 (47.6)7 (38.9)16 (45.7)5 (26.3)Height (cm)166 ± 8.3168.9 ± 7.1167.3 ± 10.1168.1 ± 11.50.555Weight (kg)80.2 ± 13.083.7 ± 10.979.1 ± 12.983.1 ± 18.30.555BMI28.9 ± 3.629.5 ± 3.528.4 ± 4.729.5 ± 4.50.792Smoking, n (%)0.079 Never Smoked12 (28.6)7 (38.9)17 (48.6)5 (26.3) Smoker11 (26.2)6 (33.3)8 (22.9)8 (42.1) Former Smoker19 (45.2)5 (27.8)10 (28.6)6 (31.6)Pack-Years5 (0–90)5 (0–60)7 (0–80)10 (0–90)0.270SBP (mmHg)137.5 ± 15.1136.7 ± 14.7147.1 ± 15.4147.5 ± 14.8 0.020* DBP (mmHg)83.9 ± 8.981.8 ± 8.689.2 ± 9.189.8 ± 9.0 0.020* HT Duration (years)4.0 (0.1–42.0)4.1 (0.5–40.0)4.2 (1.0-100)5.0 (1.0-100) 0.023* ASCVD Risk (%)10 (2.1–31.2)10.3 (2.5–32.0)12.3 (3.7–32.0)13.2 (5.6–32.0) 0.040* Risk Categories, n (%)0.234 Low2 (4.8)1 (5.3)1 (5.3)1 (5.3) Borderline7 (16.7)3 (16.7)5 (14.3)1 (5.3) Moderate25 (59.5)10 (55.6)15 (42.9)10 (52.6) High8 (19.0)4 (22.2)8 (22.9)7 (36.8) Agatston Score04 (1-106)42 (1-100)208 (106–1025) < 0.001* Comparison of demographic and clinical characteristics according to coronary artery calcium categories in hypertensive patients Agatston score and related parameters Correlation between Agatston score and related parameters are shown in Table 3. In the control group, the median Agatston score did not show a significant difference between males (median: 3 HU, range: 0–303) and females (median: 0 HU, range: 0–11) (p = 0.230). Similarly, no significant difference was observed in the Agatston score among non-smokers (median: 3 HU, range: 0–148), smokers (median: 0 HU, range: 0–303), and former smokers (median: 12 HU, range: 0–36) (p = 0.309). A positive correlation was detected between the Agatston score and ALT levels (r = 0.360, p = 0.050) as well as WBC levels (r = 0.381, p = 0.038), whereas a negative correlation was found between the Agatston score and NLR levels (r = -0.435, p = 0.016) (Table 3). Table 3Correlation between Agatston score and related parametersVariablesTotal PopulationControlHypertension r P value r P value r P valueAge0.1990.017*0.1150.5460.2050.029*Height0.1080.1990.1800.3200.0950.322Weight0.0330.697-0.0390.8560.0660.468BMI-0.0740.436-0.0890.604-0.0790.385Pack/Year0.0000.9960.2060.241-0.0460.618SBP0.1820.029*0.0900.5990.1610.087DBP0.0900.2810.0560.7310.0730.406HT Duration0.292< 0.001*--0.2930.002*ASCVD Risk Score0.292< 0.001*0.1570.4090.2930.002*Asprosin0.0200.809-0.0200.9200.0300.704Glucose0.0920.2700.0460.7740.0860.345Urea0.1230.1410.3260.0770.0920.312Creatinine-0.1110.184-0.1490.444-0.0870.336AST0.0850.3190.1200.4940.0490.592ALT0.0520.5370.0360.8580.0810.384ALP-0.1550.026*-0.1490.481-0.1910.041*GGT0.0950.2090.1360.4860.0730.398Total Cholesterol0.1050.2160.1360.4860.0920.312Triglycerides-0.0560.5020.0200.920-0.0510.579HDL-C-0.0830.333-0.1130.521-0.0600.505LDL-C0.0260.7680.0560.7310.0280.727Non-HDL-C0.0250.7680.0560.7310.0280.727TyG Index-0.0970.249-0.1130.521-0.0600.505HbA1c-0.0970.249-0.1130.521-0.0600.505WBC0.1270.1300.0380.8430.1680.038*Hemoglobin-0.0460.586-0.1110.528-0.0100.915Neutrophils0.0560.5020.0200.920-0.0510.579Lymphocytes0.0150.8490.0560.7310.0280.727Platelets0.1650.0560.1490.4440.1680.038*NLR-0.2280.006*-0.4350.016*-0.2010.030* Correlation between Agatston score and related parameters In the hypertension group, the median Agatston score did not significantly differ between males (median: 11 HU, range: 0–1025) and females (median: 3 HU, range: 0–302) (p = 0.188). Similarly, no significant difference was observed among non-smokers (median: 13 HU, range: 0–208), smokers (median: 7.5 HU, range: 0–893), and former smokers (median: 0 HU, range: 0–1025) (p = 0.683). Weak positive correlations were observed between the Agatston score and age (r = 0.205, p = 0.029) as well as ASCVD risk score (r = 0.293, p = 0.002). Conversely, a negative correlation was observed between the Agatston score and ALP levels (r = -0.191, p = 0.041) as well as NLR levels (r = -0.201, p = 0.030) (Table 3.). Risk factors associated with subclinical atherosclerosis in hypertensive patients Multivariable regression models were constructed using clinically relevant demographic, blood pressure, and metabolic variables that demonstrated significant univariable associations with atherosclerotic burden. Risk factors associated with subclinical atherosclerosis in patients with hypertension are presented in Table 4. In hypertensive patients, increasing age and higher ASCVD risk scores were independently associated with the presence of mild CAC compared with the no atherosclerosis group (β = 0.09 ± 0.03, p = 0.004; β = 0.08 ± 0.02, p = 0.002, respectively). When patients with mild CAC were compared with those with moderate CAC, systolic blood pressure and LDL-cholesterol levels were significantly associated with greater coronary calcification burden (p < 0.05 for both). The transition from moderate CAC to severe CAC was also associated with older age and elevated diastolic blood pressure (p < 0.05). Finally, when all patients with any degree of coronary calcification were compared with those without detectable calcification, the logarithmic ASCVD risk score remained the strongest independently associated factor related to subclinical atherosclerosis (β = 1.20 ± 0.37, OR = 3.32, p = 0.002). In contrast, NLR demonstrated an inverse statistical association with coronary calcification burden (β = − 0.23 ± 0.10, OR = 0.79, p = 0.030). However, this finding should be interpreted cautiously because it may reflect residual confounding, cohort selection effects, or statistical variability rather than a true biological relationship. Overall, these findings indicate that traditional cardiovascular risk factors—particularly age, blood pressure, and ASCVD risk score—were more strongly associated with subclinical atherosclerosis than inflammatory markers in this cohort (Table 4). Table 4Risk factors associated with subclinical atherosclerosis in patients with hypertensionReference GroupCompared GroupVariableβ ± SEOR (95% CI)p-valueNo atherosclerosisMild CACAge (years)0.09 ± 0.031.09 (1.03–1.16)0.004No atherosclerosisMild CACASCVD risk score (%)0.08 ± 0.021.08 (1.03–1.14)0.002Mild CACModerate CACSystolic BP (mmHg)0.03 ± 0.011.03 (1.00–1.06)0.048Mild CACModerate CACLDL-C (mg/dL)0.02 ± 0.011.02 (1.00–1.04)0.043Moderate CACSevere CACAge (years)0.10 ± 0.041.10 (1.02–1.19)0.016Moderate CACSevere CACDiastolic BP (mmHg)0.04 ± 0.021.04 (1.00–1.08)0.045No atherosclerosisAny CAC burdenASCVD risk score (log)1.20 ± 0.373.32 (1.57–7.03)0.002No atherosclerosisAny CAC burdenNLR–0.23 ± 0.100.79 (0.64–0.97)0.030 Risk factors associated with subclinical atherosclerosis in patients with hypertension ROC analysis was performed to evaluate the discriminatory performance of asprosin in identifying hypertensive patients with subclinical atherosclerosis. The analysis demonstrated that serum asprosin levels showed modest discriminatory ability between patients with and without subclinical atherosclerosis, yielding an AUC of 0.710 (95% CI: 0.62–0.80, p = 0.001). The optimal cut-off value for asprosin, determined using Youden’s index, was > 3.05 ng/mL, corresponding to a sensitivity of 69% and a specificity of 72% (Fig. 2.). ROC curve analysis evaluating the discriminatory performance of serum asprosin levels for identifying subclinical coronary calcification in hypertensive patients. The area under the curve (AUC) was 0.710 (95% CI: 0.62–0.80) Clinical findings according to hypertension duration In the group with hypertension for more than five years, the mean age was found to be higher compared to those with hypertension for five years or less (62.2 ± 5.5 years vs. 58.5 ± 7.3 years; p = 0.003). However, there were no significant differences in other demographic and clinical parameters (p > 0.05). In the group with hypertension for more than five years, mean glucose levels (93.7 ± 13.2 mg/dL vs. 87.1 ± 9.9 mg/dL; p = 0.003) and mean platelet count (274.5 ± 85.6 × 10⁹/L vs. 246.1 ± 61.8 × 10⁹/L; p = 0.042) were significantly higher compared to those with hypertension for five years or less. Conversely, the mean hemoglobin level was lower in the group with longer disease duration (14.1 ± 1.4 g/dL vs. 14.6 ± 1.3 g/dL; p = 0.027). ASCVD risk score in hypertensive patients In hypertensive patients, a positive correlation was found between the ASCVD risk score and age, systolic blood pressure (SBP), total cholesterol, LDL cholesterol, non-HDL cholesterol, WBC count, and lymphocyte levels (p < 0.05 for all). No significant correlation was observed with other demographic or clinical parameters (p > 0.05). When comparing the Moderate/High ASCVD risk group to the Low/Borderline risk group, the former had significantly higher mean age (61.1 ± 6.4 years vs. 56.4 ± 7.0 years; p = 0.002), a greater proportion of smokers (38.5% vs. 4.3%; p = 0.001), and a higher median Agatston score (13 vs. 0; p < 0.001). Other demographic parameters did not differ significantly between ASCVD risk groups (p > 0.05). Regarding laboratory findings, the Moderate/High ASCVD risk group had significantly higher median triglyceride levels (152 vs. 130; p = 0.037) and mean non-HDL cholesterol levels (166.5 ± 33.1 vs. 149.0 ± 24.3; p = 0.019). No significant differences were observed for other laboratory parameters between the risk groups (p > 0.05). Factors associated with asprosin levels In the total population, the mean asprosin levels did not show a significant difference between males and females (Males: 2.9 ± 1.0 vs. Females: 2.9 ± 0.7; p = 0.814). Similarly, there was no significant difference in asprosin levels based on smoking status (Non-smokers: 2.9 ± 1.0 vs. Smokers: 2.9 ± 0.8 vs. Former smokers: 2.8 ± 0.6; p = 0.911). A positive correlation was found between asprosin levels and triglyceride levels (r = 0.226, p = 0.003) as well as the TyG index (r = 0.326, p < 0.001), while a negative correlation was observed with HDL cholesterol levels (r = -0.174, p = 0.021). In hypertensive patients, the mean asprosin levels did not significantly differ between males and females (Males: 3.0 ± 1.0 vs. Females: 3.0 ± 0.5; p = 0.767). Likewise, no significant difference was observed based on smoking status (Non-smokers: 3.1 ± 1.1 vs. Smokers: 3.0 ± 0.6 vs. Former smokers: 2.9 ± 0.7; p = 0.489). A positive correlation was found between asprosin levels and the TyG index (r = 0.272, p = 0.003). No significant associations were found between asprosin levels and other laboratory parameters. Discussion This study was conducted to evaluate the relationship between serum asprosin levels and the Agatston score, a marker of subclinical atherosclerosis, in patients with primary hypertension. Our findings indicate that serum asprosin levels were significantly higher in hypertensive patients compared to the control group; however, no significant correlation was observed between asprosin levels and subclinical atherosclerosis. Additionally, a negative correlation was found between the Agatston score and NLR in the hypertension group. Elevated serum asprosin levels in hypertensive patients may reflect underlying metabolic-inflammatory dysregulation rather than vascular calcification activity. Previous studies have linked asprosin to insulin resistance, obesity, dyslipidemia, and inflammatory activation [15, 24]. In our cohort, despite increased serum asprosin levels, no independent association was identified between asprosin and Agatston score, suggesting that metabolic dysfunction and coronary calcification may represent partially distinct pathophysiological pathways. There is limited research on asprosin levels in hypertensive patients [24, 25]. In a study by Shafi et al., serum asprosin levels were reported to be higher in hypertensive individuals compared to controls, although this increase was also linked to obesity and insulin resistance [25]. In our study, patients with obesity and diabetes mellitus were excluded to assess whether asprosin is an independent marker of hypertension. Our findings suggest that hypertension is associated with elevated serum asprosin levels, independent of obesity and diabetes. In our study, no significant correlation was found between serum asprosin levels and the Agatston score, which is a marker of subclinical atherosclerosis. Atherosclerosis is a complex process involving inflammation, lipoprotein metabolism, oxidative stress, and endothelial dysfunction [26–29]. Previous studies have highlighted the role of pro-inflammatory cytokines such as MCP-1 and TNF-α in the development of atherosclerosis [28, 29]. Although asprosin has been shown to influence inflammation, its direct involvement in atherosclerotic processes remains unclear. A recent comprehensive review by Askin et al. further emphasized that the cardiovascular effects of asprosin appear to be highly context-dependent and may involve multiple pathways, including metabolic regulation, endothelial dysfunction, inflammatory signaling, and vascular remodeling. The authors also highlighted the need for translational studies to clarify whether circulating asprosin represents a causal mediator or merely a biomarker of cardiovascular risk [23]. Some studies suggest that asprosin may contribute to atherosclerosis by negatively affecting vascular endothelial function, particularly in conditions such as obesity and diabetes [30, 31]. However, in our study, despite higher asprosin levels in hypertensive patients, no significant association was found between asprosin and the Agatston score, supporting the hypothesis that asprosin does not directly play a role in atherosclerosis. These findings suggest that elevated asprosin levels in hypertension are more likely related to metabolic and inflammatory dysregulation rather than directly reflecting coronary atherosclerotic burden. In addition, coronary artery calcium scoring mainly reflects advanced calcified plaque burden rather than early endothelial dysfunction or metabolically active inflammatory atherosclerotic changes. Therefore, serum asprosin may be more closely related to systemic metabolic-inflammatory activation than to established coronary calcification detectable by Agatston scoring. A negative correlation was observed between the Agatston score and NLR in the hypertension group. This finding appears inconsistent with the majority of previous literature, in which elevated NLR has generally been associated with increased atherosclerotic burden and adverse cardiovascular outcomes [32–35]. Several explanations may account for this paradoxical observation. First, the relatively small sample size and cross-sectional design may have increased susceptibility to statistical variability and residual confounding. Second, the exclusion of patients with diabetes mellitus, chronic kidney disease, obesity, overt cardiovascular disease, and active inflammatory conditions may have created a metabolically restricted cohort with altered inflammatory profiles. Third, the use of coronary artery calcium scoring primarily reflects calcified plaque burden rather than active inflammatory atherosclerotic activity, which may partially explain the discordance with systemic inflammatory markers such as NLR. Therefore, the inverse association observed in this study should be interpreted cautiously and should not be considered evidence of a protective role of lower inflammatory activity against coronary calcification. An additional important consideration is the highly selected nature of the study population. Patients with diabetes mellitus, obesity, chronic kidney disease, overt cardiovascular disease, and lipid-lowering or anti-inflammatory treatment were excluded to reduce potential metabolic and inflammatory confounding. While this approach improved internal consistency for evaluating the independent relationship between hypertension and serum asprosin levels, it may also have produced a metabolically restricted cohort that does not fully reflect routine clinical hypertensive populations. Because these comorbidities are strongly linked to both systemic inflammation and atherosclerotic progression, their exclusion may have attenuated or altered the observed relationships between asprosin and coronary artery calcification. Therefore, the external validity and real-world applicability of the present findings should be interpreted cautiously. Another important consideration is that coronary artery calcium scoring primarily reflects calcified coronary plaque burden and may not fully represent systemic atherosclerosis involving other vascular territories such as the carotid, cerebral, or peripheral arteries. In addition, the relatively older age of the study population may have contributed to higher baseline coronary calcification burden independent of serum asprosin levels. Therefore, the observed findings should be interpreted within the context of an older hypertensive cohort evaluated mainly by coronary calcification imaging rather than comprehensive systemic vascular assessment. Our ROC analysis demonstrated only modest discriminatory performance of serum asprosin levels for identifying subclinical atherosclerosis. The optimal cut-off value for asprosin, determined using Youden’s index, was > 3.05 ng/mL, with 69% sensitivity and 72% specificity. However, the AUC value of 0.710 indicates only modest discriminatory performance, and therefore this finding should be interpreted cautiously rather than as evidence of strong diagnostic utility. A study by You et al. proposed that asprosin’s effects on cardiovascular disease are mediated indirectly through inflammatory and metabolic mechanisms, a hypothesis supported by our findings [31]. Therefore, asprosin should currently be interpreted as a complementary metabolic-inflammatory biomarker rather than a standalone marker of subclinical atherosclerosis. Although the present findings do not demonstrate superiority of serum asprosin over traditional cardiovascular risk factors for identifying subclinical atherosclerosis, the study still provides clinically relevant information. Specifically, the absence of an independent association between asprosin and coronary artery calcium burden in a carefully selected hypertensive cohort suggests that elevated asprosin levels may primarily reflect metabolic-inflammatory activation rather than direct vascular calcification. This distinction may contribute to a more precise understanding of the biological role of asprosin in cardiovascular disease. Clinical implications The findings of this study suggest that elevated serum asprosin levels in primary hypertension reflect underlying metabolic-inflammatory dysregulation rather than direct coronary calcification burden. Traditional cardiovascular risk factors, including age, blood pressure, and ASCVD score, remained more strongly associated with subclinical atherosclerosis than serum asprosin levels. In addition, the inverse association between NLR and coronary calcification should be interpreted cautiously because of possible residual confounding, cohort selection effects, and the cross-sectional study design. Overall, serum asprosin may be considered a complementary metabolic-inflammatory biomarker; however, further longitudinal validation is required before routine clinical application. Therefore, the present findings should be regarded as hypothesis-generating, and the potential clinical utility of serum asprosin for identifying subclinical atherosclerosis should be interpreted cautiously until confirmed by larger prospective studies and external validation cohorts. Study limitations This study has some limitations. First, the sample size is relatively limited. Additionally, the predominance of hypertensive patients in the study population may restrict the generalizability of the findings to other groups. Another important limitation is the highly selective exclusion criteria, including diabetes mellitus, obesity, chronic kidney disease, overt cardiovascular disease, and lipid-lowering or anti-inflammatory therapy. Although these exclusions were intended to reduce major metabolic and inflammatory confounding, they may have limited external validity and reduced the applicability of the findings to broader real-world hypertensive populations. Furthermore, as the study was conducted in a single center, the lack of geographical and population diversity may limit the external validity of the findings. However, one of the strengths of our study is the use of the Agatston score, which is a widely validated and clinically established tool for assessing subclinical coronary calcification and cardiovascular risk stratification. Nevertheless, coronary artery calcium scoring primarily reflects calcified coronary plaque burden and does not fully represent systemic atherosclerosis involving other vascular territories. Moreover, the exclusion of patients with metabolic disorders such as obesity and diabetes allowed for a more precise evaluation of the relationship between serum asprosin levels and hypertension. In addition, the paradoxical inverse association between NLR and Agatston score may have been influenced by selection bias, restricted patient characteristics, residual confounding, or limited statistical power. Conclusions In conclusion, this study demonstrates that serum asprosin levels are significantly higher in hypertensive patients than in controls; however, no direct relationship was observed between serum asprosin and subclinical atherosclerosis assessed by Agatston score. Although serum asprosin showed modest discriminatory performance for coronary calcification, this finding should be interpreted as exploratory and hypothesis-generating rather than evidence of established clinical utility. Serum asprosin may reflect metabolic-inflammatory alterations associated with hypertension, but its role as a complementary biomarker requires validation in larger, prospective, and more heterogeneous hypertensive populations. These conclusions are consistent with recent translational perspectives suggesting that the role of asprosin in cardiovascular disease remains incompletely understood and warrants further mechanistic and clinical investigation. Authors’ contributions M.İ.Ö. and F.A. conceived and designed the study. M.K. and M.A.K. were responsible for data collection and patient recruitment. H.A. and F.M.Y. performed the formal analysis and interpreted the results. İ.A. provided administrative and technical support for the research. M.İ.Ö. and F.A. wrote the original draft of the manuscript. M.K. prepared Figs. 1 and 2 and all supplementary materials. M.A.K., H.A., F.M.Y., and İ.A. critically revised the manuscript for important intellectual content. All authors have read and agreed to the published version of the manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee. All participants provided informed consent prior to enrollment. Consent for publication Written informed consent was obtained from all individual participants included in the study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.